MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.170
+0.010
+0.86%
After Hours: 1.190 +0.02 +1.71% 19:45 05/12 EDT
OPEN
1.190
PREV CLOSE
1.160
HIGH
1.270
LOW
1.160
VOLUME
3.80M
TURNOVER
--
52 WEEK HIGH
3.780
52 WEEK LOW
1.090
MARKET CAP
254.20M
P/E (TTM)
-0.8848
1D
5D
1M
3M
1Y
5Y
1D
Allogene Therapeutics's Earnings Outlook
Benzinga · 7h ago
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
NASDAQ · 12h ago
Weekly Report: what happened at ALLO last week (0505-0509)?
Weekly Report · 16h ago
Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures
Simply Wall St · 5d ago
Weekly Report: what happened at ALLO last week (0428-0502)?
Weekly Report · 05/05 09:09
Weekly Report: what happened at ALLO last week (0421-0425)?
Weekly Report · 04/28 09:10
Allogene Therapeutics to present updated ALLO-316 results at ASCO meeting
TipRanks · 04/23 14:21
Allogene Therapeutics To Present Updated Data From Completed Phase 1 TRAVERSE Trial Of ALLO-316 In Oral Presentation At 2025 ASCO
Benzinga · 04/23 14:13
More
About ALLO
More
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Recently
Symbol
Price
%Change

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.